Stuart Walter Peltz net worth and biography

Stuart Peltz Biography and Net Worth

CEO of PTC Therapeutics

Dr. Peltz founded PTC Therapeutics in 1998 and has served as Chief Executive Officer and a member of the board of directors since the company’s inception. Under his leadership, PTC has grown from a research organization to a publicly traded, global commercial organization with multiple approved products and a foundation of strong technology platforms that continues to drive a robust discovery pipeline for patients with rare disorders. Prior to founding PTC, Dr. Peltz was a Professor in the Department of Molecular Genetics & Microbiology at the Robert Wood Johnson Medical School, Rutgers University. Dr. Peltz is a recognized scientific leader in RNA biology in the area of post-transcriptional control processes involving mRNA turnover and translation, with more than 30 years of research and over 100 publications in this area. Dr. Peltz has received a number of business and scientific awards. Notably, he was elected as a Fellow of the American Academy for the Advancement of Science in 2010. He was recognized as PharmaVoice’s 100 Most Inspiring People in 2009 and received the Dr. Sol J. Barer Award for Vision Innovation and Leadership in 2014. Dr. Peltz received a Ph.D. from the McArdle Laboratory for Cancer Research at the University of Wisconsin.

What is Stuart Walter Peltz's net worth?: The estimated net worth of Stuart Walter Peltz is at least $7.72 million as of January 31st, 2023. Dr. Peltz owns 166,962 shares of PTC Therapeutics stock worth more than $7,720,323 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Peltz may own. Additionally, Dr. Peltz receives an annual salary of $1,540,000.00 as CEO at PTC Therapeutics. Learn More about Stuart Walter Peltz's net worth.
How old is Stuart Walter Peltz?: Dr. Peltz is currently 64 years old. There are 7 older executives and no younger executives at PTC Therapeutics. Learn More on Stuart Walter Peltz's age.
What is Stuart Walter Peltz's salary?: As the CEO of PTC Therapeutics, Inc., Dr. Peltz earns $1,540,000.00 per year. Learn More on Stuart Walter Peltz's salary.
How do I contact Stuart Walter Peltz?: The corporate mailing address for Dr. Peltz and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Stuart Walter Peltz's contact information.
Has Stuart Walter Peltz been buying or selling shares of PTC Therapeutics?: Stuart Walter Peltz has not been actively trading shares of PTC Therapeutics in the last ninety days. Most recently, Stuart Walter Peltz sold 2,320 shares of the business's stock in a transaction on Tuesday, January 31st. The shares were sold at an average price of $45.63, for a transaction totalling $105,861.60. Following the completion of the sale, the chief executive officer now directly owns 166,962 shares of the company's stock, valued at $7,618,476.06. Learn More on Stuart Walter Peltz's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 253,856 shares worth more than $12,039,652.16. The most recent insider tranaction occured on December, 2nd when insider Neil Gregory Almstead sold 69,550 shares worth more than $3,620,773.00. Insiders at PTC Therapeutics own 5.5% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 12/2/2024.

Stuart Walter Peltz Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/31/2023	Sell	2,320	$45.63	$105,861.60	166,962
1/24/2023	Sell	284	$47.45	$13,475.80	55,204
1/11/2023	Sell	1,189	$44.36	$52,744.04	169,282
1/9/2023	Sell	1,786	$41.66	$74,404.76	171,699
6/7/2022	Sell	407	$26.83	$10,919.81	38,239
4/14/2022	Sell	82	$45.28	$3,712.96	38,646
2/1/2022	Sell	1,961	$40.00	$78,440.00
1/25/2022	Sell	330	$39.31	$12,972.30
1/4/2022	Sell	378	$41.16	$15,558.48
2/1/2021	Sell	1,968	$56.96	$112,097.28	80,315
1/25/2021	Sell	350	$62.05	$21,717.50
1/5/2021	Sell	1,402	$62.37	$87,442.74	54,683
12/30/2020	Sell	285,718	$61.74	$17,640,229.32	225,866
12/7/2020	Sell	348,417	$61.00	$21,253,437.00	248,877
11/4/2020	Sell	49,365	$60.00	$2,961,900.00
11/2/2020	Sell	50,000	$53.66	$2,683,000.00	106,085
10/6/2020	Sell	124,351	$50.12	$6,232,472.12	56,985
7/15/2020	Sell	100,000	$55.70	$5,570,000.00	106,085
5/20/2020	Sell	33,788	$50.00	$1,689,400.00	89,873
5/5/2020	Sell	109,928	$50.34	$5,533,775.52	166,013
1/23/2020	Sell	423	$53.25	$22,524.75
1/6/2020	Sell	1,797	$48.17	$86,561.49	23,085
12/3/2019	Sell	22,463	$49.43	$1,110,346.09
1/7/2019	Sell	2,512	$34.75	$87,292.00	24,882
1/5/2018	Sell	2,230	$18.03	$40,206.90	26,646
6/9/2015	Sell	100,000	$54.49	$5,449,000.00
6/8/2015	Sell	73,700	$54.91	$4,046,867.00
3/23/2015	Sell	47,200	$69.14	$3,263,408.00
3/9/2015	Sell	47,201	$70.74	$3,338,998.74
10/1/2014	Sell	41,501	$42.65	$1,770,017.65
3/24/2014	Sell	25,487	$29.86	$761,041.82	135,902
3/7/2014	Sell	27,414	$29.91	$819,952.74	161,389

Stuart Walter Peltz Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $46.24

$44.74

$47.42

50 Day Range

MA: $43.50

$36.70

$52.07

2 Week Range

Now: $46.24

$23.58

$54.16

Volume

1,431,601 shs

Average Volume

849,432 shs

Market Capitalization

$3.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

Stuart Peltz Biography and Net Worth

What is Stuart Walter Peltz's net worth?

How old is Stuart Walter Peltz?

What is Stuart Walter Peltz's salary?

How do I contact Stuart Walter Peltz?

Has Stuart Walter Peltz been buying or selling shares of PTC Therapeutics?

Who are PTC Therapeutics' active insiders?

Are insiders buying or selling shares of PTC Therapeutics?